Professor Peter Schmid is the Clinical Director of the St. Bartholomew Breast Cancer Centre, and Honorary Consultant Medical Oncologist and lead of the Cancer Immune Therapy group at Barts Hospital. He is also Professor of Cancer Medicine and Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute.
Professor Schmid studied medicine in Munich and Aberdeen. He was awarded scholarships by the German National Academic Foundation, the German Academic Exchange Service and the Hanns-Seidel-Foundation. Following this he completed specialist training in internal medicine, medical oncology and haematology in Berlin. Subsequently he undertook an MD in Clinical Chemistry at the Technical University Munich and a PhD in Medical Oncology at the Charité University in Berlin. In 2005, Professor Schmid moved to the UK and was appointed as Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. He was subsequently made Foundation Chair in Cancer Medicine at the University of Sussex.
He specialises in breast cancer, lung cancer and cancer immune therapy and is renowned internationally for this work in cancer immunotherapy. He was instrumental in the formation of the Cancer Immune Therapy group at Barts Hospital, which has become recognised globally as a leader in this field.
Professor Schmid has a particular research interest in triple negative breast cancer and endocrine resistance and has led more than 20 clinical studies and several translational research programmes in these areas. He also has an interest in personalised cancer medicine using novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. He currently leads an international group to establish blood-based circulating biomarkers.
He has authored or co-authored more than 150 publications and has published a book on the management of bone metastases. He is also regularly invited to speak at major international cancer conferences. Professor Schmid is a member of the breast cancer faculty of the European Society of Medical Oncology and has chaired several medical research committees. He was awarded the Breast Cancer Research Award 2012 by German Patient group Mammazone.
Professor Schmid has a strong interest in patient-doctor communication, for a number of years, he ran a programme training oncologists and oncology nurses in communication.
It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.Diseases, Medical Tests and Treatments